Product Description
Mechanisms of Action: CYP17 Inhibitor, AR Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Innocrin
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Renal Cell Carcinoma|Low Back Pain|Glioblastoma|Head and Neck Cancer|Thyroid Cancer|Goodpasture Syndrome|Small Cell Carcinoma|Basal Cell Carcinoma|Prostate Cancer|Melanoma|Neck Pain|Breast Cancer|Salivary Gland Cancer|Bladder Cancer|Small Cell Sarcoma|Triple Negative Breast Cancer|Male Breast Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04947189 |
4CAST | P2 |
Recruiting |
Triple Negative Breast Cancer |
2026-07-01 |
2025-05-16 |
Primary Endpoints |
|
NCT03600467 |
START | P2 |
Terminated |
Small Cell Carcinoma|Glioblastoma|Basal Cell Carcinoma|Prostate Cancer|Goodpasture Syndrome|Small Cell Sarcoma|Low Back Pain|Salivary Gland Cancer|Thyroid Cancer|Renal Cell Carcinoma|Neck Pain|Melanoma|Breast Cancer|Head and Neck Cancer|Bladder Cancer |
2021-02-28 |
2022-09-30 |
Primary Endpoints|Treatments |
|
2011-004103-20 |
2011-004103-20 | P2 |
Completed |
Prostate Cancer |
2019-01-23 |
2025-06-02 |
Treatments |
|
NCT02580448 |
CLARITY-01 | P2 |
Completed |
Male Breast Cancer|Triple Negative Breast Cancer |
2019-01-01 |
50% |
2019-03-22 |
|
NCT02012920 |
INO-VT-464-CL-001 | P2 |
Completed |
Prostate Cancer |
2018-12-01 |
12% |
2019-03-20 |
Primary Completion Date |
NCT02445976 |
INO-VT-464-CL-003 | P2 |
Completed |
Prostate Cancer |
2018-12-01 |
50% |
2019-03-20 |
Primary Completion Date |
NCT02361086 |
INO-VT-464-CL-004 | P2 |
Completed |
Prostate Cancer |
2017-12-01 |
12% |
2019-03-20 |
Treatments|Trial Status |
NCT02130700 |
INO-VT-464-CL-002 | P2 |
Completed |
Prostate Cancer|Triple Negative Breast Cancer |
2017-09-01 |
2019-03-20 |
Treatments |